Oscar Segurado | |
|---|---|
 | |
| Born | 25 March 1958 |
| Known for | Founder and executive director of MedicAffairs Consulting LLC, President of the Neo Chi Institute |
| Scientific career | |
| Fields | Gene Therapy, Gene Editing, Cell Therapy, Rare Diseases, Oncology, Hematology, Hematooncology, Rheumatotogy, Cardiovascular, Metabolic and Immune-Mediated Diseases, Neuroimmunology, Autoimmunity |
| Institutions | ASC Therapeutics, Symvivo, Myriad Genetics-Crescendo, CellMax Life, Becton Dickinson, Abbott |
Oscar Segurado is a medical researcher and academician. He holds a tenured professorship of Immunology at the University of León, Spain. Segurado has conducted research in the domains of Rheumatology and Immunology. His scientific work focuses on Rheumatoid arthritis.
He received his Ph.D. from the University of Wuerzburg, Germany, and his MD from the University of Salamanca, Spain. [1]
Segurado served as an Associate professor at the Faculties of Medicine in the Ludwig Maximilian University of Munich, Germany, and Complutense University of Madrid, Spain, and was later awarded tenure professorship at University of León. [2] He has published papers focusing on Gene therapy (ASC, AveXis, UCLA Ventures, UniQure, and Symvivo), immuno-oncology (Amgen, AstraZeneca, Bellicum, and Jazz), immuno-therapy (Bristol-Myers Squibb, Macrogenics, and TriSalus), genomics (Freenome, Myriad) and protein/cell diagnostics (Abbott, BD, and Crescendo), predominantly focused on Oncology, Hematology, and Autoimmunity, including personalized medicine, molecular and cellular biomarkers. [3]
- Lee, Y.C.; Hackett, J.; Frits, M.; Iannaccone, C.K.; Shadick, N.A.; Weinblatt, M.E.; Segurado, O.G.; Sasso, E.H. (2016). "Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia". Rheumatology. 55 (4): 640–648. doi: 10.1093/rheumatology/kev388. PMC 4795537. PMID 26608972.
- Davies, A.; Cifaldi, M.A.; Segurado, O.G.; Weisman, M.H. (2009). "Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis". The Journal of Rheumatology. 36 (1): 16–26. doi: 10.3899/jrheum.080257. PMID 19012363. S2CID 40436997.
- Pincus, P.; Amara, I.; Segurado, O.G.; Bergman, M.; Koch, G.G. (2008). "Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials". The Journal of Rheumatology. 4 (2): 109–116. doi: 10.1586/17434440.4.2.109. PMID 17359217. S2CID 1027814.
- Weinblatt, E. C.; Furst, D. E.; Kavanaugh, A.F.; Chartash, E. K.; Segurado, O. G. (2006). "Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year comprehensive study". Annals of the Rheumatic Diseases. 65 (6): 753–759. doi: 10.1136/ard.2005.044404. PMC 1798163. PMID 16308341.
- Schendel, D.J.; Gansbacher, B.; Oberneder, R.; Kriegmair, M.; Hofstetter, A.; Riethmüller, G.; Segurado, O.G. (1993). "Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines". The Journal of Immunology. 151 (8): 4209–4220. doi: 10.4049/jimmunol.151.8.4209. PMID 8409397. S2CID 25708001.
- Mindful Framing: Transform Your Anxiety Into Vital Energy (2018) [4]
- ^ "Oscar Segurado". Forbes Councils. Retrieved 2022-09-15.
- ^ "Oscar Segurado, MD, PhD | The Conference Forum". 2019-12-16. Retrieved 2022-09-15.
- ^ "Oscar Segurado". Gene Therapy Medical Affairs. Retrieved 2022-09-15.
- ^ Segurado, Oscar (25 March 2018). Kirkus Reviews (Mindful Framing). ISBN 9780692050989.
Oscar Segurado | |
|---|---|
|
| |
| Born | 25 March 1958 |
| Known for | Founder and executive director of MedicAffairs Consulting LLC, President of the Neo Chi Institute |
| Scientific career | |
| Fields | Gene Therapy, Gene Editing, Cell Therapy, Rare Diseases, Oncology, Hematology, Hematooncology, Rheumatotogy, Cardiovascular, Metabolic and Immune-Mediated Diseases, Neuroimmunology, Autoimmunity |
| Institutions | ASC Therapeutics, Symvivo, Myriad Genetics-Crescendo, CellMax Life, Becton Dickinson, Abbott |
Oscar Segurado is a medical researcher and academician. He holds a tenured professorship of Immunology at the University of León, Spain. Segurado has conducted research in the domains of Rheumatology and Immunology. His scientific work focuses on Rheumatoid arthritis.
He received his Ph.D. from the University of Wuerzburg, Germany, and his MD from the University of Salamanca, Spain. [1]
Segurado served as an Associate professor at the Faculties of Medicine in the Ludwig Maximilian University of Munich, Germany, and Complutense University of Madrid, Spain, and was later awarded tenure professorship at University of León. [2] He has published papers focusing on Gene therapy (ASC, AveXis, UCLA Ventures, UniQure, and Symvivo), immuno-oncology (Amgen, AstraZeneca, Bellicum, and Jazz), immuno-therapy (Bristol-Myers Squibb, Macrogenics, and TriSalus), genomics (Freenome, Myriad) and protein/cell diagnostics (Abbott, BD, and Crescendo), predominantly focused on Oncology, Hematology, and Autoimmunity, including personalized medicine, molecular and cellular biomarkers. [3]
- Lee, Y.C.; Hackett, J.; Frits, M.; Iannaccone, C.K.; Shadick, N.A.; Weinblatt, M.E.; Segurado, O.G.; Sasso, E.H. (2016). "Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia". Rheumatology. 55 (4): 640–648. doi: 10.1093/rheumatology/kev388. PMC 4795537. PMID 26608972.
- Davies, A.; Cifaldi, M.A.; Segurado, O.G.; Weisman, M.H. (2009). "Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis". The Journal of Rheumatology. 36 (1): 16–26. doi: 10.3899/jrheum.080257. PMID 19012363. S2CID 40436997.
- Pincus, P.; Amara, I.; Segurado, O.G.; Bergman, M.; Koch, G.G. (2008). "Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials". The Journal of Rheumatology. 4 (2): 109–116. doi: 10.1586/17434440.4.2.109. PMID 17359217. S2CID 1027814.
- Weinblatt, E. C.; Furst, D. E.; Kavanaugh, A.F.; Chartash, E. K.; Segurado, O. G. (2006). "Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year comprehensive study". Annals of the Rheumatic Diseases. 65 (6): 753–759. doi: 10.1136/ard.2005.044404. PMC 1798163. PMID 16308341.
- Schendel, D.J.; Gansbacher, B.; Oberneder, R.; Kriegmair, M.; Hofstetter, A.; Riethmüller, G.; Segurado, O.G. (1993). "Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines". The Journal of Immunology. 151 (8): 4209–4220. doi: 10.4049/jimmunol.151.8.4209. PMID 8409397. S2CID 25708001.
- Mindful Framing: Transform Your Anxiety Into Vital Energy (2018) [4]
- ^ "Oscar Segurado". Forbes Councils. Retrieved 2022-09-15.
- ^ "Oscar Segurado, MD, PhD | The Conference Forum". 2019-12-16. Retrieved 2022-09-15.
- ^ "Oscar Segurado". Gene Therapy Medical Affairs. Retrieved 2022-09-15.
- ^ Segurado, Oscar (25 March 2018). Kirkus Reviews (Mindful Framing). ISBN 9780692050989.